Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 2, Randomized, Double Blinded, Study of Nivolumab (BMS-936558) in Combination With Ipilimumab vs Ipilimumab Alone in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma
Brief Summary: The primary purpose of this study is to compare the objective response rate, as determined by investigators, of Nivolumab combined with Ipilimumab versus Ipilimumab monotherapy in patients with untreated, unresectable, or metastatic melanoma


Options:
A: Arm Label: Arm A (nivolumab, surgery); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Biological: Nivolumab, Procedure: Therapeutic Conventional Surgery | Arm Label: Arm B (nivolumab, ipilimumab, surgery); Type: EXPERIMENTAL; Interventions: Biological: Ipilimumab, Other: Laboratory Biomarker Analysis, Biological: Nivolumab, Procedure: Therapeutic Conventional Surgery | Arm Label: Arm C (nivolumab, relatlimab, surgery); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Biological: Nivolumab, Biological: Relatlimab, Procedure: Therapeutic Conventional Surgery | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Arm B (nivolumab, ipilimumab, surgery) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm A (nivolumab, surgery), Arm B (nivolumab, ipilimumab, surgery), Arm C (nivolumab, relatlimab, surgery) | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm A (nivolumab, surgery), Arm B (nivolumab, ipilimumab, surgery), Arm C (nivolumab, relatlimab, surgery) | Intervention Type: BIOLOGICAL; Name: Relatlimab; Assigned to Arm(s): Arm C (nivolumab, relatlimab, surgery) | Intervention Type: PROCEDURE; Name: Therapeutic Conventional Surgery; Assigned to Arm(s): Arm A (nivolumab, surgery), Arm B (nivolumab, ipilimumab, surgery), Arm C (nivolumab, relatlimab, surgery)
B: Arm Label: Treatment (dabrafenib, trametinib, surgery); Type: EXPERIMENTAL; Interventions: Drug: Dabrafenib, Other: Laboratory Biomarker Analysis, Procedure: Therapeutic Conventional Surgery, Drug: Trametinib | Intervention Type: DRUG; Name: Dabrafenib; Assigned to Arm(s): Treatment (dabrafenib, trametinib, surgery) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Treatment (dabrafenib, trametinib, surgery) | Intervention Type: PROCEDURE; Name: Therapeutic Conventional Surgery; Assigned to Arm(s): Treatment (dabrafenib, trametinib, surgery) | Intervention Type: DRUG; Name: Trametinib; Assigned to Arm(s): Treatment (dabrafenib, trametinib, surgery)
C: Arm Label: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab, Drug: Ipilimumab | Arm Label: Placebo + Ipilimumab; Type: EXPERIMENTAL; Interventions: Drug: Ipilimumab, Drug: Placebo | Intervention Type: DRUG; Name: Nivolumab; Assigned to Arm(s): Nivolumab + Ipilimumab | Intervention Type: DRUG; Name: Ipilimumab; Assigned to Arm(s): Nivolumab + Ipilimumab, Placebo + Ipilimumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Ipilimumab
D: Arm Label: Arm I (aldesleukin); Type: EXPERIMENTAL; Interventions: Biological: Aldesleukin, Other: Quality-of-Life Assessment, Other: Questionnaire Administration, Other: Laboratory Biomarker Analysis | Arm Label: Arm II (gp100 antigen in Montanide IDA-51 and aldesleukin); Type: EXPERIMENTAL; Interventions: Biological: Aldesleukin, Biological: gp100 Antigen, Drug: Montanide ISA 51 VG, Other: Quality-of-Life Assessment, Other: Questionnaire Administration, Other: Laboratory Biomarker Analysis | Intervention Type: BIOLOGICAL; Name: Aldesleukin; Assigned to Arm(s): Arm I (aldesleukin), Arm II (gp100 antigen in Montanide IDA-51 and aldesleukin) | Intervention Type: BIOLOGICAL; Name: gp100 Antigen; Assigned to Arm(s): Arm II (gp100 antigen in Montanide IDA-51 and aldesleukin) | Intervention Type: DRUG; Name: Montanide ISA 51 VG; Assigned to Arm(s): Arm II (gp100 antigen in Montanide IDA-51 and aldesleukin) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm I (aldesleukin), Arm II (gp100 antigen in Montanide IDA-51 and aldesleukin) | Intervention Type: OTHER; Name: Questionnaire Administration; Assigned to Arm(s): Arm I (aldesleukin), Arm II (gp100 antigen in Montanide IDA-51 and aldesleukin) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (aldesleukin), Arm II (gp100 antigen in Montanide IDA-51 and aldesleukin)

Answer: C